# Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

> **NCT05751187** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Non-squamous NSCLC

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DIETARY_SUPPLEMENT:** Folic acid 350-1000 μg
- **DIETARY_SUPPLEMENT:** Vitamin B12 1000 μg
- **DRUG:** Dexamethasone 4 mg

## Key facts

- **NCT ID:** NCT05751187
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-27
- **Primary completion:** 2025-12-15
- **Final completion:** 2027-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751187, "Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05751187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*